Katarina Miljević/LinkedIn
Jul 15, 2026, 13:43
Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
Katarina Miljević, Postdoctoral Research Scientist at the Department of Clinical Pharmacology, Medical University of Vienna, shared a post on LinkedIn:
“I was delighted to present two posters at the ISTH 2026 Congress in Paris, highlighting research from the Department of Clinical Pharmacology MedUni Vienna, focusing on:
- Pharmacokinetic and pharmacodynamic equivalence of recombinant tPA products
- FXI inhibition with cenvacibart and its effects on hemodialysis circuit clotting
Grateful to all collaborators and co-authors who contributed to these projects.
Looking forward to the discussions and future research opportunities.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge